Fernand Labrie

Publications

Page 2 of 2, showing 13 records out of 63 total, starting on record 51, ending on 63

Publication Category Year
13. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. Acolbifene 1998
12. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. Acolbifene 1998
11. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β. Endocrinology, 139: 111-118. Acolbifene 1998
10. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. Acolbifene 1998
9. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. Acolbifene 1997
8. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long term inhibitory effects of a novel antiestrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. Acolbifene 1997
7. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. Acolbifene 1997
6. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. Acolbifene 1997
5. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. Acolbifene 1997
4. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. Acolbifene 1997
3. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. Acolbifene 1997
2. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. Acolbifene 1997
1. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. Acolbifene 1997
<< previous | 1 | 2
next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards